Jump to content
  • Virtual Coffee Mornings

    Members only. Share, discuss, problem solve.

    Reserve your place
  • 2021 European QA Symposium

    The Future of Quality: What's keeping you awake at night? 20th - 21st May 2021

    More Information
  • Refresh your GLP skills

    Remote course now available.

    Book Now

*Please note that while still operational, the RQA office is being run remotely, so please bear with us if we take a little longer than usual to deal with any queries*

Who are RQA

The Research Quality Association (RQA) is a professional membership body dedicated to informing and advancing its members. We provide status and visibility for individuals engaged in the quality of research concerning pharmaceuticals, agrochemicals, chemicals and medical devices. Since our inception in 1977, the Association has increased and evolved to reflect regulatory changes, the growing impact of regulatory inspection and the ever-changing structure and needs of industry. RQA's purpose is to drive quality and integrity in scientific research.  

Read more+

Our vision

To inspire quality, integrity and compliance in scientific research.

Our mission

To provide knowledge and learning in the scientific research community by building expertise through training, communication, engagement and collaboration.


Sign up to the latest news and events.

Latest News

View all news

EMA - public consultation on European Health Data Space (EHDS)

We would like to inform you that the European Commission has launched a public consultation on European Health Data Space (EHDS), which aims to make full use of digital health to provide high-quality healthcare and reduce inequalities. It will promote access to health data for prevention, diagnosis and treatment, research and innovation, as well as for policy-making and legislation.

Read more+

International regulators and WHO call for wider public access to clinical data

The International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO) are urging pharmaceutical companies to publish clinical trial reports for new medicines and vaccines without redactions to ensure that research results are publicly accessible to all those involved in healthcare decision-making. In a joint statement, they stress that systematic transparency can increase trust in regulatory decision-making, reassure the public about data integrity and can stimulate research and development, which could have a positive impact on vaccine confidence.

Read more+

MHRA - Guidance on the licensing of biosimilar products

MHRA have produced a new 'Guidance on the licensing of biosimilar products'.

Read more+